- Home
- ACHV vs CRDL Comparison
ACHV vs CRDL Comparison
Compare ACHV & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- CRDL
- Stock Information
- Founded
- ACHV N/A
- CRDL 2017
- Country
- ACHV Canada
- CRDL Canada
- Employees
- ACHV N/A
- CRDL N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACHV Health Care
- CRDL Health Care
- Exchange
- ACHV Nasdaq
- CRDL Nasdaq
- Market Cap
- ACHV 72.5M
- CRDL 80.1M
- IPO Year
- ACHV N/A
- CRDL N/A
- Fundamental
- Price
- ACHV $3.58
- CRDL $1.25
- Analyst Decision
- ACHV Strong Buy
- CRDL Strong Buy
- Analyst Count
- ACHV 3
- CRDL 3
- Target Price
- ACHV $14.33
- CRDL $9.00
- AVG Volume (30 Days)
- ACHV 234.9K
- CRDL 156.5K
- Earning Date
- ACHV 05-13-2025
- CRDL 05-14-2025
- Dividend Yield
- ACHV N/A
- CRDL N/A
- EPS Growth
- ACHV N/A
- CRDL N/A
- EPS
- ACHV N/A
- CRDL N/A
- Revenue
- ACHV N/A
- CRDL N/A
- Revenue This Year
- ACHV N/A
- CRDL N/A
- Revenue Next Year
- ACHV N/A
- CRDL N/A
- P/E Ratio
- ACHV N/A
- CRDL N/A
- Revenue Growth
- ACHV N/A
- CRDL N/A
- 52 Week Low
- ACHV $1.84
- CRDL $0.77
- 52 Week High
- ACHV $5.58
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- ACHV 69.97
- CRDL 63.31
- Support Level
- ACHV $2.89
- CRDL $1.04
- Resistance Level
- ACHV $3.32
- CRDL $1.31
- Average True Range (ATR)
- ACHV 0.25
- CRDL 0.07
- MACD
- ACHV 0.06
- CRDL 0.01
- Stochastic Oscillator
- ACHV 95.12
- CRDL 77.94
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.